Renewal Of Marketing Authorisation, The Mutual Recognition Secondoprocedura, Of The Medicinal Product For Human Use "perindopril Ranbaxy», Resulting In A Review Printed.

Original Language Title: Rinnovo dell'autorizzazione all'immissione in commercio, secondoprocedura di mutuo riconoscimento, del medicinale per uso umano«Perindopril Ranbaxy», con conseguente modifica stampati.

Read the untranslated law here: http://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.dataPubblicazioneGazzetta=2015-03-19&atto.codiceRedazionale=15A01893&elenco30giorni=false&atto.tipoProvvedimento=DECRETO

Retrieved February 18, 2015 2015 of # 50/PV determines Medicine: PERINDOPRIL 4 mg tablets: 038523 015 "Packs" RANBAXY 14 tablets in PVC/AL 038523 027 "4 mg tablets" 30 tablets in PVC/AL 038523 039 "4 mg tablets" 60 tablets in PVC/AL 038523 041 "4 mg tablets" 90 tablets in PVC/AL 038523 054 "4 mg tablets" 500 tablets in PVC/AL hospital Pack 4 mg tablet "14" 038523 066 tablets in PA/AL/PVC-AL 038523 078 "4 mg tablets" 30 tablets in PA/AL/PVC-AL 038523 080 "4 mg tablets" 60 tablets in PA/AL/PVC-AL 038523 092 "4 mg tablets" 90 tablets in PA/AL/PVC-AL 038523 104 "4 mg tablets" 500 tablets in PA/AL/PVC-AL bulk package Mah: Ranbaxy Italy S.p.a.
Mutual recognition procedure NL/H/0977/002/R/001 date of 4/24/2012 is renewed, with unlimited validity, the marketing authorisation subject to amendment of the summary of product characteristics, package leaflet and labelling and on condition that, on the date of entry into force of this determination, the requirements of quality, safety and efficacy are still present.
It also approved the change in NL/H/0977/002/IB/013/G-C1B/2014/2580, updating of the summary of product characteristics and package leaflet.
Changes must be made immediately to the summary of the product characteristics as per the package leaflet and labelling no later than six months after its publication in the Official Gazette of the Italian Republic of this determination.
In accordance with art. 80, paragraphs 1 and 3, of Legislative Decree No 219 April 24, 2006 and s leaflet and labels must be written in Italian and, limited to medicinal products marketed in the province of Bolzano, in German. The mAh avails itself of the complementary use of foreign languages, must give prior notice to the AIFA and keep available the certified translation of German texts and/or in another foreign language. In case of non-compliance with the provisions on the labelling and package leaflet shall apply sanctions under art. 82 of the Decree.
Both lots already products as of the date of publication in the official journal of the Italian Republic of this determination that the batches produced during the period referred to in art. 2, paragraph 2, of the aforementioned determination, which did not indicate the changes authorized, can be kept on the market until the expiration date printed on the label of the medicine. Pharmacists are required to deliver the package leaflet updated users as from the end of 30 days from the date of publication in the Official Gazette of the Italian Republic of this determination. The mAh makes accessible to pharmacist leaflet updated within the same timeframe.
This determination takes effect from the day following that of its publication in the official journal of the Italian Republic and will be notified to the company holder of the marketing authorisation of the medicinal product.